Cipla reports consolidated PAT of Rs. 675.80 Cr

Cipla has reported total income of Rs. 7,280.82 crore during the period ended December 31, 2025

Cipla launches needle-free inhalable insulin Afrezza in India

Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge

Pfizer and Cipla forge exclusive marketing and distribution pact for key brands in India

This marks the first partnership between Pfizer and Cipla in India

Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India

Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors

Venus Remedies secures final Rs. 11 crore payment from Cipla for AMR drug

The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019

Cipla opens India's First dedicated lung health diagnostics center in Delhi

Cipla to acquire Inzpera Healthsciences for Rs. 110.65 Cr

The transaction is expected to be completed within one month from the signing of the definitive agreements.

Cipla posts consolidated Q2 FY26 PAT Rs. 1,351.17 Cr

Cipla has reported total income of Rs. 7,858.39 crore during the period ended September 30, 2025

Cipla to sell Lilly's weight-loss drug under new brand in India

Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors

Briefs: Nectar Lifesciences, Cipla and Marksans Pharma

Marksans Pharma gets USFDA nod for acid reflux drug